Please assess the completion status of the following clinical trial:

Trial Title: AD109 Dose Finding in Mild to Moderate OSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* AHI between 5 and 20 events/h~* PGI-S equal to or higher than 1, or one or more of the following symptoms:~  * Snoring or nightime gasping/choking~ * Daytime sleepiness, fatigue or decreased concentration~ * Nonrefreshing sleep, sleep fragmentation (including from nocturia), or morning headache~ * Irritability, decreased mood or libido~Exclusion Criteria:~* History of narcolepsy.~* Clinically significant craniofacial malformation.~* Clinically significant cardiac disease (e.g. rhythm disturbances, coronary artery disease or heart failure or hypertension requiring more than 2 medications for control).~* CPAP should not be used for at least 2 weeks prior to the study~* History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used during participation in the study.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sequence ABC (Type: OTHER): AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B), then Placebo (C).
- Sequence ACB (Type: OTHER): AD109 Dose 1- 75 mg (A), then Placebo (C) then AD109 Dose 2- 37.5 mg (B)
- Sequence BAC (Type: OTHER): AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A), then Placebo (C)
- Sequence BCA (Type: OTHER): AD109 Dose 2- 37.5 mg (B), then Placebo (C), then AD109 Dose 1- 75 mg (A)
- Sequence CAB (Type: OTHER): Placebo (C), then AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B)
- Sequence CBA (Type: OTHER): Placebo (C), then AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A)

Based on this trial design, predict the completion outcome and termination type (if applicable).